Metabolomic strategies to identify tissue-specific effects of cardiovascular drugs

Minna T. Jänis, Reijo Laaksonen, Matej Orešič

Research output: Contribution to journalArticleScientificpeer-review

13 Citations (Scopus)


Background: The number of patients eligible for cardiovascular therapies in general is forecast to increase substantially in the coming decades. However, the current list of potential future cardiovascular blockbuster drugs is alarmingly short. There is thus a clear need for innovative strategies to increase the efficiency of drug development pipelines by establishing new sensitive biomarkers to monitor drug efficacy and safety in the context of complexity of lipoprotein metabolism targeted by the cardiovascular drugs. Methods: Metabolomics is a discipline dedicated to the systematic study of small molecules in cells, tissues and biofluids. Since lipids (including cholesterol), as well as other metabolites, are key constituents of lipoprotein particles and are thus part of the complex lipoprotein metabolism that includes exchange of lipids and metabolites with peripheral tissues, cardiovascular drug safety and efficacy needs to be addressed in the context of systemic lipid metabolism. Results/conclusion: Metabolomics, lipidomics in particular, is expected to make an important impact on the discovery and development of cardiovascular therapies.
Original languageEnglish
Pages (from-to)665-680
JournalExpert Opinion on Drug Metabolism and Toxicology
Issue number6
Publication statusPublished - 2008
MoE publication typeA1 Journal article-refereed


  • cardiovascular disease
  • drug safety
  • lipid-lowering drugs
  • lipidomics
  • metabolomics
  • myopathy
  • pathway analysis
  • pharmacology
  • statins
  • toxicology
  • translational medicine


Dive into the research topics of 'Metabolomic strategies to identify tissue-specific effects of cardiovascular drugs'. Together they form a unique fingerprint.

Cite this